Is ZNTL or LONA more profitable?

Zentalis Pharmaceuticals' return on equity of -70.18% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Zentalis Pharmaceuticals N/A -70.18% -51.46% Athira Pharma N/A -411.58% -225.73%

Do analysts prefer ACB or LONA?

Athira Pharma has a consensus target price of $17.33, indicating a potential upside of 194.28%. Given Athira Pharma's higher probable upside, analysts plainly believe Athira Pharma is more favorable than Aurora Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Athira Pharma 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has higher earnings and valuation, CRDL or LONA?

Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardiol Therapeutics N/A N/A -$24.20M -$0.25 N/A Athira Pharma N/A N/A -$105.61M -$4.21 N/A

Is CRDL or LONA more profitable?

Cardiol Therapeutics' return on equity of -180.44% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Cardiol Therapeutics N/A -180.44% -140.28% Athira Pharma N/A -411.58% -225.73%

Do analysts prefer SIGA or LONA?

Athira Pharma has a consensus target price of $17.33, indicating a potential upside of 194.28%. Given Athira Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Athira Pharma is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Athira Pharma 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Do analysts recommend SBTX or LONA?

Athira Pharma has a consensus target price of $17.33, suggesting a potential upside of 194.28%. Given Athira Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Athira Pharma is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Athira Pharma 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has better valuation and earnings, SBTX or LONA?

Silverback Therapeutics is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A Athira Pharma N/A N/A -$105.61M -$4.21 N/A

Is SBTX or LONA more profitable?

Silverback Therapeutics' return on equity of -29.62% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Silverback Therapeutics N/A -29.62% -28.20% Athira Pharma N/A -411.58% -225.73%

Athira Pharma (LONA) Competitors

$5.89 -0.16 (-2.64%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$6.70 +0.81 (+13.75%)

As of 05:11 AM Eastern

Compare

LONA vs. ZNTL, ACB, CRDL, SIGA, and SBTX

Should you buy Athira Pharma stock or one of its competitors? Athira Pharma's main competitors and comparable companies include Zentalis Pharmaceuticals (ZNTL), Aurora Cannabis (ACB), Cardiol Therapeutics (CRDL), Siga Technologies (SIGA), and Silverback Therapeutics (SBTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Athira Pharma compare to Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Athira Pharma (NASDAQ:LONA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Zentalis Pharmaceuticals has a beta of 1.85, meaning that its stock price is 85% more volatile than the broader market. Comparatively, Athira Pharma has a beta of 2.05, meaning that its stock price is 105% more volatile than the broader market.

Zentalis Pharmaceuticals presently has a consensus price target of $6.75, indicating a potential upside of 135.19%. Athira Pharma has a consensus price target of $17.33, indicating a potential upside of 194.28%. Given Athira Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Athira Pharma is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.40
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Zentalis Pharmaceuticals' return on equity of -70.18% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%
Athira Pharma	N/A	-411.58%	-225.73%

57.1% of Athira Pharma shares are held by institutional investors. 3.8% of Zentalis Pharmaceuticals shares are held by insiders. Comparatively, 25.7% of Athira Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Athira Pharma has lower revenue, but higher earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43M	3.05	-$137.06M	-$1.95	N/A
Athira Pharma	N/A	N/A	-$105.61M	-$4.21	N/A

In the previous week, Zentalis Pharmaceuticals had 1 more articles in the media than Athira Pharma. MarketBeat recorded 1 mentions for Zentalis Pharmaceuticals and 0 mentions for Athira Pharma. Zentalis Pharmaceuticals' average media sentiment score of 0.31 beat Athira Pharma's score of 0.00 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Zentalis Pharmaceuticals	Neutral
Athira Pharma	Neutral

Summary

Zentalis Pharmaceuticals and Athira Pharma tied by winning 7 of the 14 factors compared between the two stocks.

How does Athira Pharma compare to Aurora Cannabis?

Aurora Cannabis (NASDAQ:ACB) and Athira Pharma (NASDAQ:LONA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

In the previous week, Aurora Cannabis had 3 more articles in the media than Athira Pharma. MarketBeat recorded 3 mentions for Aurora Cannabis and 0 mentions for Athira Pharma. Aurora Cannabis' average media sentiment score of 0.47 beat Athira Pharma's score of 0.00 indicating that Aurora Cannabis is being referred to more favorably in the media.

Company	Overall Sentiment
Aurora Cannabis	Neutral
Athira Pharma	Neutral

Aurora Cannabis has higher revenue and earnings than Athira Pharma. Aurora Cannabis is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurora Cannabis	$247.82M	1.10	-$88.13M	-$1.41	N/A
Athira Pharma	N/A	N/A	-$105.61M	-$4.21	N/A

Athira Pharma has a consensus target price of $17.33, indicating a potential upside of 194.28%. Given Athira Pharma's higher probable upside, analysts plainly believe Athira Pharma is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurora Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

47.6% of Aurora Cannabis shares are held by institutional investors. Comparatively, 57.1% of Athira Pharma shares are held by institutional investors. 0.0% of Aurora Cannabis shares are held by insiders. Comparatively, 25.7% of Athira Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Athira Pharma has a net margin of 0.00% compared to Aurora Cannabis' net margin of -32.26%. Aurora Cannabis' return on equity of 4.37% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurora Cannabis	-32.26%	4.37%	3.45%
Athira Pharma	N/A	-411.58%	-225.73%

Aurora Cannabis has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market. Comparatively, Athira Pharma has a beta of 2.05, meaning that its stock price is 105% more volatile than the broader market.

Summary

Aurora Cannabis beats Athira Pharma on 8 of the 15 factors compared between the two stocks.

How does Athira Pharma compare to Cardiol Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Athira Pharma (NASDAQ:LONA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.

Cardiol Therapeutics has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market. Comparatively, Athira Pharma has a beta of 2.05, indicating that its share price is 105% more volatile than the broader market.

Cardiol Therapeutics currently has a consensus price target of $10.00, indicating a potential upside of 464.97%. Athira Pharma has a consensus price target of $17.33, indicating a potential upside of 194.28%. Given Cardiol Therapeutics' higher probable upside, equities analysts plainly believe Cardiol Therapeutics is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Cardiol Therapeutics had 4 more articles in the media than Athira Pharma. MarketBeat recorded 4 mentions for Cardiol Therapeutics and 0 mentions for Athira Pharma. Cardiol Therapeutics' average media sentiment score of 0.45 beat Athira Pharma's score of 0.00 indicating that Cardiol Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cardiol Therapeutics	Neutral
Athira Pharma	Neutral

Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A
Athira Pharma	N/A	N/A	-$105.61M	-$4.21	N/A

Cardiol Therapeutics' return on equity of -180.44% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-180.44%	-140.28%
Athira Pharma	N/A	-411.58%	-225.73%

12.5% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 57.1% of Athira Pharma shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by insiders. Comparatively, 25.7% of Athira Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Cardiol Therapeutics beats Athira Pharma on 7 of the 12 factors compared between the two stocks.

How does Athira Pharma compare to Siga Technologies?

Siga Technologies (NASDAQ:SIGA) and Athira Pharma (NASDAQ:LONA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

55.4% of Siga Technologies shares are owned by institutional investors. Comparatively, 57.1% of Athira Pharma shares are owned by institutional investors. 2.7% of Siga Technologies shares are owned by company insiders. Comparatively, 25.7% of Athira Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Siga Technologies has higher revenue and earnings than Athira Pharma. Siga Technologies is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siga Technologies	$94.57M	2.41	$23.28M	-$0.05	N/A
Athira Pharma	N/A	N/A	-$105.61M	-$4.21	N/A

Athira Pharma has a consensus target price of $17.33, indicating a potential upside of 194.28%. Given Athira Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Athira Pharma is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Athira Pharma has a net margin of 0.00% compared to Siga Technologies' net margin of -5.19%. Siga Technologies' return on equity of -1.55% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Siga Technologies	-5.19%	-1.55%	-1.32%
Athira Pharma	N/A	-411.58%	-225.73%

In the previous week, Siga Technologies' average media sentiment score of 0.80 beat Athira Pharma's score of 0.00 indicating that Siga Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Siga Technologies	Positive
Athira Pharma	Neutral

Siga Technologies has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, Athira Pharma has a beta of 2.05, suggesting that its stock price is 105% more volatile than the broader market.

Summary

Athira Pharma beats Siga Technologies on 8 of the 14 factors compared between the two stocks.

How does Athira Pharma compare to Silverback Therapeutics?

Silverback Therapeutics (NASDAQ:SBTX) and Athira Pharma (NASDAQ:LONA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

In the previous week, Silverback Therapeutics' average media sentiment score of 0.00 equaled Athira Pharma'saverage media sentiment score.

Company	Overall Sentiment
Silverback Therapeutics	Neutral
Athira Pharma	Neutral

74.9% of Silverback Therapeutics shares are owned by institutional investors. Comparatively, 57.1% of Athira Pharma shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by company insiders. Comparatively, 25.7% of Athira Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Silverback Therapeutics is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A
Athira Pharma	N/A	N/A	-$105.61M	-$4.21	N/A

Silverback Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market. Comparatively, Athira Pharma has a beta of 2.05, suggesting that its share price is 105% more volatile than the broader market.

Athira Pharma has a consensus target price of $17.33, suggesting a potential upside of 194.28%. Given Athira Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Athira Pharma is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Silverback Therapeutics' return on equity of -29.62% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silverback Therapeutics	N/A	-29.62%	-28.20%
Athira Pharma	N/A	-411.58%	-225.73%

Summary

Silverback Therapeutics beats Athira Pharma on 6 of the 11 factors compared between the two stocks.

Get Athira Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LONA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LONA vs. The Competition

Export

Metric	Athira Pharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$56.83M	$12.60B	$7.31B	$13.29B
Dividend Yield	N/A	2.63%	2.52%	12.57%
P/E Ratio	-1.40	792.28	274.09	25.69
Price / Sales	N/A	861.37	642.55	79.71
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	1.98	10.58	10.47	6.32
Net Income	-$105.61M	$2.81B	$3.49B	$359.73M
7 Day Performance	-15.25%	-0.12%	-0.68%	0.17%
1 Month Performance	-23.80%	-1.34%	-3.18%	-3.27%
1 Year Performance	N/A	2.86%	15.12%	5.58%

Athira Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LONA Athira Pharma	2.3521 of 5 stars	$5.89 -2.6%	$17.33 +194.3%	N/A	$56.83M	N/A	N/A	19	Gap Up
ZNTL Zentalis Pharmaceuticals	3.7345 of 5 stars	$3.13 -10.6%	$6.75 +115.7%	+91.3%	$250.85M	$67.43M	N/A	106	Gap Up
ACB Aurora Cannabis	1.0257 of 5 stars	$3.82 +0.3%	N/A	-16.1%	$247.05M	$247.82M	N/A	1,028	News Coverage
CRDL Cardiol Therapeutics	2.6846 of 5 stars	$1.85 -7.0%	$10.00 +440.5%	+62.4%	$231.19M	N/A	N/A	18	News Coverage Analyst Forecast
SIGA Siga Technologies	0.7192 of 5 stars	$2.98 -5.4%	N/A	-65.0%	$226.33M	$94.57M	N/A	49

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LONA) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Athira Pharma (LONA) Competitors

LONA vs. ZNTL, ACB, CRDL, SIGA, and SBTX

How does Athira Pharma compare to Zentalis Pharmaceuticals?

Summary

How does Athira Pharma compare to Aurora Cannabis?

Summary

How does Athira Pharma compare to Cardiol Therapeutics?

Summary

How does Athira Pharma compare to Siga Technologies?

Summary

How does Athira Pharma compare to Silverback Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LONA vs. The Competition

Athira Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Athira Pharma (LONA) Competitors

LONA vs. ZNTL, ACB, CRDL, SIGA, and SBTX

How does Athira Pharma compare to Zentalis Pharmaceuticals?

Which has more risk & volatility, ZNTL or LONA?

Do analysts recommend ZNTL or LONA?

Is ZNTL or LONA more profitable?

Do institutionals and insiders believe in ZNTL or LONA?

Which has better earnings and valuation, ZNTL or LONA?

Does the media favor ZNTL or LONA?

Summary

How does Athira Pharma compare to Aurora Cannabis?

Does the media favor ACB or LONA?

Which has higher earnings & valuation, ACB or LONA?

Do analysts prefer ACB or LONA?

Do institutionals & insiders believe in ACB or LONA?

Is ACB or LONA more profitable?

Which has more volatility & risk, ACB or LONA?

Summary

How does Athira Pharma compare to Cardiol Therapeutics?

Which has more volatility & risk, CRDL or LONA?

Do analysts rate CRDL or LONA?

Does the media favor CRDL or LONA?

Which has higher earnings and valuation, CRDL or LONA?

Is CRDL or LONA more profitable?

Do insiders & institutionals believe in CRDL or LONA?

Summary

How does Athira Pharma compare to Siga Technologies?

Do insiders and institutionals believe in SIGA or LONA?

Which has preferable valuation & earnings, SIGA or LONA?

Do analysts prefer SIGA or LONA?

Is SIGA or LONA more profitable?

Does the media prefer SIGA or LONA?

Which has more risk & volatility, SIGA or LONA?

Summary

How does Athira Pharma compare to Silverback Therapeutics?

Does the media refer more to SBTX or LONA?

Do insiders & institutionals hold more shares of SBTX or LONA?

Which has better valuation and earnings, SBTX or LONA?

Which has more risk & volatility, SBTX or LONA?

Do analysts recommend SBTX or LONA?

Is SBTX or LONA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LONA vs. The Competition

Athira Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools